What Is Tesamorelin?

Also known as: Egrifta

Tesamorelin is a stabilized GHRH analog and the clinical heavyweight of the family: FDA-approved as Egrifta for reducing excess visceral abdominal fat in HIV-associated lipodystrophy. Its trials showed 15-18% visceral fat reduction over 26 weeks — measured by CT scan, not before/after photos.

That evidence made it the off-label darling of metabolic and longevity clinics targeting deep belly fat, the metabolically dangerous kind. It is dosed higher (2 mg daily) and priced accordingly.

What is Tesamorelin studied for?

Side effects & safety

Trial-documented: injection-site reactions, joint aches, fluid retention, and glucose-tolerance drift requiring monitoring in longer runs. The most 'known quantity' of any GH-axis peptide.

Legal & approval status

FDA-approved pharmaceutical (Egrifta) for its specific indication; off-label and research-market use extends well beyond it. WADA-banned.

Typical dosing at a glance

Commonly reported protocols use 1 mg–2 mg, daily, via subcutaneous injection. For the mixing math — how much bacteriostatic water, exact syringe units, doses per vial — see the Tesamorelin reconstitution calculator →

Related peptides

What is Ipamorelin?What is CJC-1295 (no DAC)?What is CJC-1295 DAC?What is Sermorelin?What is Hexarelin?

Educational overview based on published research and commonly reported community protocols — not medical advice, and not an endorsement of any compound. Consult a licensed healthcare provider.